Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Authors
Keywords
Multiple myeloma, Allo-HCT, Autologous HCT, Allogeneic hematopoietic cell transplantation, Stem cell transplantation
Journal
Current Hematologic Malignancy Reports
Volume 12, Issue 2, Pages 126-135
Publisher
Springer Nature
Online
2017-03-11
DOI
10.1007/s11899-017-0374-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Advances in understanding prognosis in myeloma
- (2016) Dean Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
- (2016) A. Paviglianiti et al. HAEMATOLOGICA
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
- (2016) A. Paviglianiti et al. HAEMATOLOGICA
- Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation
- (2015) Koji Kawamura et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
- (2015) Nina Shah et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma
- (2015) L Giaccone et al. BONE MARROW TRANSPLANTATION
- A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) D. M. Benson et al. CLINICAL CANCER RESEARCH
- Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
- (2015) B. Paiva et al. CLINICAL CANCER RESEARCH
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
- (2014) Melissa Alsina et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia
- (2014) A. J. de Smith et al. BLOOD
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
- (2014) Loren Gragert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma
- (2013) T Nishihori et al. BONE MARROW TRANSPLANTATION
- Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation
- (2013) C O Freytes et al. BONE MARROW TRANSPLANTATION
- Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients
- (2013) Teresa Caballero-Velázquez et al. BRITISH JOURNAL OF HAEMATOLOGY
- WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions
- (2012) E. M. Tyler et al. BLOOD
- Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
- (2012) H. M. Lokhorst et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
- (2012) Christine Wolschke et al. EXPERIMENTAL HEMATOLOGY
- Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant
- (2012) Amer M. Beitinjaneh et al. LEUKEMIA & LYMPHOMA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
- (2011) Qaiser Bashir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
- (2011) Francesca Patriarca et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
- (2011) S. Kumar et al. BLOOD
- Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
- (2011) E. Kneppers et al. BLOOD
- Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
- (2011) D. Roos-Weil et al. HAEMATOLOGICA
- Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
- (2011) Bo Björkstrand et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
- (2011) Amrita Krishnan et al. LANCET ONCOLOGY
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
- (2010) Henk Lokhorst et al. JOURNAL OF CLINICAL ONCOLOGY
- Ex vivoInhibition of NF-κB Signaling in Alloreactive T-cells Prevents Graft-Versus-Host Disease
- (2009) M. J. O'Shaughnessy et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Defining the Intensity of Conditioning Regimens: Working Definitions
- (2009) Andrea Bacigalupo et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
- (2009) M Kapp et al. BONE MARROW TRANSPLANTATION
- Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma
- (2009) Nicolaus Kröger et al. EXPERIMENTAL HEMATOLOGY
- Comparison of Twin and Autologous Transplants for Multiple Myeloma
- (2008) Asad Bashey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
- (2008) B. Bruno et al. BLOOD
- A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
- (2008) L. Rosinol et al. BLOOD
- Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity
- (2008) D. Pende et al. BLOOD
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
- (2008) M. Rotta et al. BLOOD
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
- (2008) J. El-Cheikh et al. HAEMATOLOGICA
- Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
- (2008) G Schilling et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More